Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
eNq1mFFv2jAQx9/5FFEe9kYCbSl0S6g21m5IrcZo0aa9IJMcxSzY6dmmsE8/h4BKJ0ftDH7ggTj539l3/vkvR5erReYtAQXlLPabQcP3gCU8pewh9kf31/WOf9mtRXOyJHuvtYNG0DzxvSQjQsR+MRpMgDAR/Ly9+Qz6e0C/W/MiPplDIl+8pyTNgq9EzG5JXrzjRUtOU28BcsbT2M+V3Dz1IiFRZ9F94vhb5CSBKNw+2R+dj8/2n0dhIfYGVSUAbwh7MIoCs9JMFCIw2SMSHjiuK/I9tdKmYgiCK0xgQORsgHxJU0iNIaYkE2AVZPqU3gEuM5BFEKN4OE8WwkqczMlqCI99c9If9WhPrmS9UW+2z1v6177onLXtiot7S2Wugp5EmIw75zrKSQgsJInuyrXlslEx4ChJ5qgqVPReNpajOAiPr1Y/pSLPyDqYi9x2qQgSPQyot7+7iRQzuEcNpEyv2T/6TGVZ+J9Zj7a4cJRxQaMeV0xWUON6aLsQPc4krKoragc6udr2IgVxPNk/nJkhP1CTjCa2SNPQUSDkaNivJtoxYfCJCBihOxr8oCzlT+L4lNmvqqPs8w0ojaI5ps3xyUXnvNlqWW+iX7qFKk6YK4U8h1Dzh4pDsNJnU34oUHRXmqV2PXm0dtz4HJ6QDCqcTt2SLboPd8bMWae720XlgFH0y9W9bXt8V4Dru81fozRN411h7bjrAua6F1/Lu9y1cT4+bbQ6F6dn78gi/7Bz0LGlWy5FnZhlhWbEzKTMxfswnBFRF0SvZTDFavxfGqd9jKlr1j5X0p2Xd3L2l16o5Kyj1CflAfr2Etru19ecwaFud/v91lUbY0hUcEAdSrQ7A3D/6vhMf7a6ztIevECLuzAbW0ok5cyVXVITo+JBp4guK7tGzYZv0ymtuFapbMsoLK90urUoLK5zurW/51X+FQ==
6VjT6QJrXK1BfX7m
Listen
